New IBD drug candidate INT-210 begins first human safety tests
NCT ID NCT07616791
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tested the safety and tolerability of INT-210 capsules in 86 healthy adults aged 18-45. Participants received single or multiple doses of the drug or a placebo, and researchers monitored side effects and how the drug moves through the body. The study also looked at whether food affects drug absorption. This is an early step toward possibly developing a treatment for inflammatory bowel disease (IBD).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- INT-210 capsule
- What this could lead to
- If successful, this early safety study could pave the way for future trials testing INT-210 as a treatment for inflammatory bowel disease.
- What could go wrong
- This is a very early Phase 1 trial in healthy people, not patients. It only tests safety and dosing, not whether the drug works for IBD. Many drugs fail in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBD (INFLAMMATORY BOWEL DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Municipality - Beijing Municipality - No. 101, Luyuan East Road, Tongzhou District, Beijing
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sleep hormone melatonin put to the test for IBD patients with poor sleep
- Which diet do IBD patients prefer? intermittent fasting, mediterranean, or low FODMAP?
- Could a postbiotic soothe irritable bowel syndrome?
- Podcast vs. pamphlet: which boosts IBD knowledge best?
- New oral drug for inflammatory bowel disease enters first human tests
- Double-Drug attack on stubborn IBD shows promise